SCHEMBL963423

SCHEMBL963423

Cc1ccc(S(=O)(=O)NC(=O)C=Cc2c(C)nn(C)c2-n2ccc3cc(Cl)ccc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.41
FLT4 P35916 3/20 0.41
KDR P35968 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 1/20 0.39
NR2F2 P24468 1/20 0.39
HTT P42858 1/20 0.39
PTGER3 P43115 2/20 0.38
PHGDH O43175 3/20 0.37
EGFR P00533 2/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL963421 1.00 FLT1 (0.41) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL962598 0.96 PTGER3 (0.41) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL962596 0.96 PTGER3 (0.41) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL965317 0.93 PTGER3 (0.40) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL965316 0.93 PTGER3 (0.40) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL962857 0.92 FLT1 (0.43) FLT1FLT4KDRMAPTPTGER3
SCHEMBL962859 0.92 FLT1 (0.43) FLT1FLT4KDRMAPTPTGER3
SCHEMBL965340 0.91 FLT1 (0.40) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL965338 0.91 FLT1 (0.40) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL964365 0.90 PTGER3 (0.44) FLT1FLT4KDRSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 FLT1 1862/4885FLT4 2164/4885KDR 3801/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG FLT1 1015/4885FLT4 915/4885KDR 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.